Gefitinib in combination with bevacizumab as first-line therapy seems to be a favorable and well-tolerated treatment for patients with advanced NSCLC with activating EGFR gene mutations, especially those with EGFR exon 19 deletion mutations, although the primary end point was not met because the lower limit of the CI was less than 40%.

This study demonstrated prospectively the feasibility of short-term low-volume hydration.

No abstract

This prospective study demonstrated the safety and efficacy of shorter-term lower-volume hydration.